Filipa C. Lynce

The paper shows BRCA-mutant breast cancers respond to PARP inhibitors with immune remodeling, but PD-L1 blockade is ineffective due to spatial separation of PD-L1+ cells and PD-1+ T cells.

The paper develops predictive models using patient-derived breast cancer organoids to identify drug responses and guide new therapies for resistant disease.

This study analyzes genomic alterations in a large IBC cohort, finding high TP53 mutation frequency and NOTCH pathway enrichment, but no major genomic differences compared to non-IBC cases.